MedTrace Logo

Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma

NCT00227695 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2019-05-15

No results posted yet for this study

Summary

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known whether giving rituximab over a short period of time is more effective than giving it over a long period of time in treating follicular non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is studying rituximab to see how well it works when given over a short period of time compared to when given over a long period of time in treating patients with follicular non-Hodgkin's lymphoma.

Conditions

Interventions

BIOLOGICAL

rituximab

comparing two maintenance schedules of Rituximab

Sponsors & Collaborators

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Christian Taverna, MD · Kantonsspital Münsterlingen

  • Michele Ghielmini, Prof. · IOSI - Ospedale San Giovanni, Bellinzona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-08
Primary Completion
2013-05-03
Completion
2017-12-19

Countries

  • Brazil
  • Italy
  • North Macedonia
  • Serbia
  • Slovakia
  • South Africa
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00227695 on ClinicalTrials.gov